Introduction
============

Hepatocellular carcinoma (HCC) is the sixth most common form of cancer ([@b1-ol-0-0-10024]) and is the third most common cause of cancer-associated mortality worldwide ([@b2-ol-0-0-10024]). Hepatitis B virus (HBV) infection is one of the important etiological factors that can lead to liver damage. It was estimated that \~5% of the world population are infected with HBV, especially in China ([@b3-ol-0-0-10024]). A large proportion of patients with chronic HBV infection may develop necroinflammatory liver disease in the order of increasing severity from sustained liver injury to cirrhosis, hepatic failure and HCC ([@b4-ol-0-0-10024]). Early diagnosis and treatment are vital for improving the overall survival rate of patients with HCC. The detection of serum a fetoprotein (AFP) may aid the diagnosis of HCC, but its sensitivity is low, especially at the early stage of HCC. Therefore, it is critical to find novel non-invasive serum biomarkers for the independent or combined diagnosis of HCC.

MicroRNA (miRNA), a type of small non-coding single stranded RNA of 18--25 nucleotides in length, can interact with the target genes to suppress their expression by promoting the degradation of target genes or inhibiting translation ([@b5-ol-0-0-10024],[@b6-ol-0-0-10024]). miRNAs have a wide range of functions and are involved in a variety of biological processes, including cell proliferation, growth, differentiation, apoptosis, metabolism and signaling pathway transduction ([@b7-ol-0-0-10024],[@b8-ol-0-0-10024]). They may also serve as important clinical biomarkers for the diagnosis and prognosis of multiple types of cancer ([@b9-ol-0-0-10024]--[@b11-ol-0-0-10024]). miRNA-122 is one of the key biomarkers of the miRNAs and constitutes \~52% of the total hepatic miRNome ([@b12-ol-0-0-10024]). It is the most abundant liver-specific miRNA, which has notable anti-inflammatory effects and is involved in a variety of liver functions ([@b13-ol-0-0-10024],[@b14-ol-0-0-10024]). It has been reported that miRNA-122 exhibited dysregulated expression in HCC tissues, serum and cell lines ([@b15-ol-0-0-10024],[@b16-ol-0-0-10024]); however, contradictory conclusions regarding the differential expression and prognosis of miRNA-122 have been reported ([@b17-ol-0-0-10024]). In addition, the numerous functions of miRNA-122 in HCC and other types of cancer remain to be further investigated.

In the present study, the clinical value and associated function of miRNA-122 in various types of cancer, particularly in HCC were systematically analyzed. Firstly, the expression levels of miRNA-122 in patients with HCC, benign and healthy groups were analyzed and the significance of miRNA-122 and AFP in the differential diagnosis of HCC was evaluated. Secondly, the analysis on the differential expression and survival rate of miRNA-122 in a variety of common cancer types using miRNA-seq data from The Cancer Genome Atlas (TCGA; <http://cancergenome.nih.gov/>) was performed. Thirdly, the target genes of miRNA-122 were comprehensively predicted for further functional enrichment analysis. Finally, the associated research progress of miRNA-122 was systematically summarized. The content of the present study was progressive and may improve current understanding of miRNA-122 from a macroscopic and comprehensive perspective.

Materials and methods
=====================

### Serum sample collection

The present study was approved by the Institutional Review Board of the First Affiliated Hospital of Guangxi Medical University (Guangxi, China) and written informed consent was obtained from all individuals in this research project. A total of 150 individuals were enrolled from September 2016 to September 2017, including patients with HCC (50 cases), patients with benign lesions (50 cases) and healthy controls (50 cases). Patent characteristics are presented in [table I](#tI-ol-0-0-10024){ref-type="table"}. HCC patients were diagnosed by serum AFP concentration analysis and abdominal ultrasonography; diagnoses were confirmed by histopathological examination. In addition, all the serum samples of HCC patients were collected prior to surgical resection. All the serum samples were collected, centrifuged at 2,000 × g for 5 min at room temperature and stored as 500-µl aliquots at −80°C prior to experimental use.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) experiment

Total RNA of serum samples was extracted using the Serum/Plasma miRNA Extraction and Isolation kit DP503. This kit is a newly-developed products specifically for serum and plasma miRNA extraction. Total RNA was reverse transcribed using the miRcute Enhanced miRNA cDNA First Strand Synthesis kit (KR211). All the reagents were obtained from Tiangen Biotech Co., Ltd. (Beijing, China) and all operations were conducted in strict accordance with the manufacturer\'s protocol. The temperature protocol was as follows: 60 min for miRNA plus A tail reaction and reverse transcription reaction at 42°C; 3 min for enzyme inactivation reaction at 95°C. The RT-qPCR experiment was performed using the reagent of SYBR-Green FP411. The thermocycling conditions of the RT-qPCR were as follows: 15 min for initial template denaturation at 95°C, following 45 cycles of PCR template denaturation for 20 sec at 94°C; annealing and extension for 34 sec at 60°C. The melting/dissociation curve stage was produced following RT-qPCR. The 7500 Real-Time PCR Instrument from Thermo Fisher Scientific, Inc. (Waltham, MA, USA) was used in the detection. U6 was set as an internal reference. The primer of U6: Forward: 5′-AGCGGGAAATCGTGCGTGACA-3′, reverse: 5′-GTGGACTTGGGAGAGGACTGG-3′. The primer of miRNA-122: Forward: 5′-GCGAAAGCATTTGCCAAGAA-3′, reverse: 5′-CATCACAGACCTGTTATTGC-3′. Calculation of the relative miRNA expression levels was based on 2^−ΔΔCq^ ([@b18-ol-0-0-10024]).

### Statistical analysis

The values in tables were reported as the mean ± standard deviation or number percentage, unless otherwise stated. The receiver operating characteristic curve, area under curve (AUC), sensitivity, specificity, positive predictive value and negative predictive value (NPV) were used to analyze diagnostic accuracy. Youden index=sensitivity-(1-specificity). When the Youden index is at its maximum, the corresponding detection value can be used as the cutoff ([@b19-ol-0-0-10024]). Student\'s t-test or one-way analysis of variance (ANOVA) was used to analyze continuous variables where appropriate in this study. Student\'s t-test was used for the analysis of differential expression between two groups and the one-way ANOVA was used for the analysis of differential expression among more than two groups. Bonferroni\'s post hoc test was used following the ANOVA. The χ^2^ test or Fisher\'s exact test was used for the comparisons of differences in the categorical data between groups. A two-tailed P≤0.05 was considered to indicate a statistically significant difference. The aforementioned analyses were performed using IBM SPSS 20.0 (IBM, Corps., Armonk, NY, USA). The scatter plot was produced using GraphPad Prism 5 software (Graphpad Software, Inc., La Jolla, CA, USA).

### Differential expression and survival analysis of miRNA-122 in TCGA and literature summary in PubMed

At present, a number of studies have demonstrated that miRNAs or other genes frequently exhibit diversity as clinical markers of cancer. The diagnosis and prognosis of a certain biomarker in clinical pan-cancer is also a popular research model ([@b20-ol-0-0-10024],[@b21-ol-0-0-10024]). Therefore, data of TCGA was thoroughly used to analyze the expression levels of miRNA-122 in a variety of common tumors in this study. Data mining is one of the hot topics in bioinformatics research. The statistical results are more scientific and accurate than simple difference analysis. TCGA is currently a popular database for cancer research. It is a project initiated by the National Cancer Institute and the National Human Genome Research Institute in 2005. It has provided a large amount of genomic data and associated clinical data for researchers in basic and translational medicine for cancer. In this study, analysis of differential expression was performed on the basis that cancer tissues and para-cancerous tissues must be present simultaneously. In TCGA database, the number of tumor tissues are greater than the normal tissues. Certain types of tumor do not contain normal tissue samples. Therefore, the criteria that adjacent normal tissue samples ≥3 was set. The 'edgeR' package of R (version 3.3.3; <http://www.r-project.org>) was used for differential expression analysis based on a False Discovery Rate \<0.05 and the absolute value of log~2~ (fold change) ≥1. In addition, the overall survival analysis of cancers with differentially expressed miRNA-122 was performed using the 'survival' package of R (<http://bioconductor.org/packages/3.6/bioc/>). The present study also searched for relevant references by searching the keyword 'miRNA-122' or 'microRNA-122' or 'miR-122' in PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), and summarized the expression and prognosis of miRNA-122 in various types of cancer.

### Target gene prediction and functional enrichment analysis

The target gene prediction software available for miRNA is multifarious. In the present study, four classical and common sets of software were selected to predict the target gene of miRNA-122, including miRanda (<http://www.microrna.org/>) ([@b22-ol-0-0-10024]), Pic Tar (<http://pictar.mdc-berlin.de/>) ([@b23-ol-0-0-10024]), miRDB (<http://www.mirdb.org/>) ([@b24-ol-0-0-10024]) and TargetScanHuman (<http://www.targetscan.org/vert_71/>) ([@b25-ol-0-0-10024]), respectively. Comparing the target genes of the four types of software, the intersection of any two predictor softwares were selected as candidate target genes for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway functional enrichment analyses. The Venn diagram demonstrating intersections were constructed using the 'VennDiagram' package of R. Furthermore, the GO and KEGG pathway analyses are the most common functional enrichment analyses and were performed using the online software, Database for Annotation, Visualization and Integrated Discovery (DAVID), version 6.8 (<https://david.ncifcrf.gov/>) ([@b26-ol-0-0-10024]). The selection criteria for functional items were in accordance with P≤0.05 and count number ≥2.

Results
=======

### Clinical characteristics

The clinical information and laboratory biomarker analysis of the different groups are presented in [Table I](#tI-ol-0-0-10024){ref-type="table"}. For statistical analysis, all the participants were divided into three groups: Including HCC (50 cases), benign (HBV and cirrhosis, 50 cases) and healthy (50 cases). There was no statistically significant difference between the age and gender of the studied groups as they were matched with each other. However, there was a significant difference between the different groups regarding the clinical biomarker AFP (P\<0.001 for all comparisons).

### Different expression of miRNA-122 among three groups

The expression levels of miRNA-122 were detected among the HCC, benign and healthy groups. The results indicated that there was a significant difference in the expression levels of miRNA-122 among the three groups ([Fig. 1](#f1-ol-0-0-10024){ref-type="fig"}). Compared with the healthy group, the HCC and benign groups exhibited significantly increased expression levels of miRNA-122 (P\<0.001). In addition, the expression levels of miRNA-122 between the HCC and benign groups were compared, and it was demonstrated that the benign group exhibited significantly higher expression levels of miRNA-122 compared with the HCC group (P=0.007). Overall, the expression levels of miRNA-122 in the healthy, HCC and benign groups demonstrated a stepwise increase (healthy group \< HCC group \< benign group); there was a statistically significant difference between the groups (P\<0.001; [Fig. 1C](#f1-ol-0-0-10024){ref-type="fig"}). Therefore, miRNA-122 can be used not only for the identification of HCC and normal controls, but also for the identification of HCC and benign lesions. There is also a study demonstrating that the serum level of miRNA-122 in patients with hepatitis is increased compared with in HCC patients ([@b27-ol-0-0-10024]). The experiments of the present study confirmed this.

### Subgroup analysis of miRNA-122 in individuals with HBV

In the study of the clinical markers of HCC, it is particularly important to analyze individuals with hepatitis B. Therefore, subgroup analysis (HBV-positive and -negative groups) of the expression levels in individuals with hepatitis B was performed in the present study. The results are presented in [Table II](#tII-ol-0-0-10024){ref-type="table"}. There was no statistically significant difference in the expression levels of miRNA-122 between the positive and negative HBV groups. However, the concentration of AFP was significantly associated with HBV infection in the HCC (P=0.03) and HCC + Benign group (P=0.003). In HBV-infected individuals, AFP concentrations were increased compared with HBV negative patients.

### Diagnostic accuracy of miRNA-122, AFP and miRNA-122 + AFP

In the previous differential expression analysis, it was demonstrated that the miRNA-122 expression levels were significantly different between the HCC vs. healthy groups and the HCC vs. benign groups ([Fig. 1](#f1-ol-0-0-10024){ref-type="fig"}). Additionally, AFP has also been recognized as a serological biomarker for the diagnosis of HCC. Therefore, the diagnostic value of assessing miRNA-122, AFP and miRNA-122 + AFP in HCC was investigated in the present study ([Table III](#tIII-ol-0-0-10024){ref-type="table"}). The diagnostic sensitivity of miRNA-122 (sensitivity, 90%) was increased compared with AFP (sensitivity, 86%) and the combination of the two biomarkers could further improve the diagnostic accuracy between the HCC and healthy groups (AUC, 0.980; 95% CI, 0.958--1.000). However, the diagnostic sensitivity and specificity of miRNA-122 were poor between HCC and benign groups (sensitivity, 64%; specificity, 62%).

### Differential expression and survival analysis of miRNA-122 by pan-cancer analysis of TCGA database

It is an indisputable fact that miRNA-122 is highly expressed in HCC. However, the expression of miRNA-122 in other types of tumor requires further investigation. In the present study, the differential expression of miRNA-122 was analyzed in a variety of common tumors using the publicly available data of TCGA database. Following strict screening, 17 types of cancer were selected to analyze the differential expression of miRNA-122 between cancerous and adjacent normal tissues; the results are presented in [Table IV](#tIV-ol-0-0-10024){ref-type="table"}. The expression levels of miRNA-122 were significantly upregulated in eight types of cancer, including colorectal carcinoma, breast, kidney and lung cancers, prostate adenocarcinoma, stomach adenocarcinoma, thyroid carcinoma and uterine cancer. In addition, miRNA-122 was reported to be significantly downregulated in cholangiocarcinoma and HCC ([Table IV](#tIV-ol-0-0-10024){ref-type="table"}). Simultaneously, survival analysis was performed in the types of cancer with differentially expressed miRNA-122. The results of survival analysis demonstrated that high expression levels of miRNA-122 were associated with poor prognosis in kidney cancer, but good in patients with HCC (P=0.012 and P\<0.001). However, there was no significant effects on the prognoses of other types of cancer ([Fig. 2](#f2-ol-0-0-10024){ref-type="fig"}).

### Literature summary of the expression and prognosis of miRNA-122 via pan-cancer analysis

In addition to experimental validation and public database mining, the collective findings of the literature were also valuable. Information from available articles on the PubMed database on differential expression levels and prognostic value of miRNA-122 in a variety of cancer types was summarized. The results are presented in [Table V](#tV-ol-0-0-10024){ref-type="table"}. Literature data of the differential expression and survival analysis of miRNA-122 between HCC and adjacent normal tissues were consistent with the results of TCGA analysis. Additionally, the results in colorectal cancer, renal carcinoma, cholangiocarcinoma, prostate cancer and thyroid carcinoma were the same. However, there were inconsistent conclusions of particular types of cancer, including breast and gastric cancer. The inconsistencies need to be further studied.

### Target gene prediction of miRNA-122 and functional enrichment analysis

Due to the limitations of using a single prediction software of miRNA target genes, four commonly used miRNA target gene prediction software were used to simultaneously analyze. The intersection of two or more of the employed software was selected. Finally, 353 miRNA-122 target genes were included for functional enrichment analysis ([Fig. 3](#f3-ol-0-0-10024){ref-type="fig"}). MEF2C, MASP1, SLC52A2, NONO, BRPF1, USP53, VPS4A, CCAR1, H1F0 and KIF5B were the top 10 of the 353 target genes, and the others are not illustrated. In the present study, GO and KEGG pathway analysis were carried on the target genes of miRNA-122. Following the enrichment analysis by DAVID software, 68 notable GO items were identified, of which 38 items for 'biological process' (BP), 8 items for 'cellular component' (CC) and 22 items for 'molecular function' (MF). In addition, six important KEGG signaling pathways were also identified. The top 10 items from different categories are presented in [Figs. 4](#f4-ol-0-0-10024){ref-type="fig"} and [5](#f5-ol-0-0-10024){ref-type="fig"}. The results indicated that cardiac muscle cell differentiation and glucose metabolic process items in BP, the perinuclear region of cytoplasm and cytoplasmic microtubule items in CC, protein binding and double-stranded RNA binding items in MF, mucin type O-glycan biosynthesis and epithelial cell signaling in *Helicobacter pylori* infection items of the KEGG signaling pathways were the most closely associated with the target genes of miRNA-122.

Discussion
==========

Although research regarding the expression levels and associated functions of miRNA-122 in HCC and other liver diseases have been widely carried out ([@b15-ol-0-0-10024],[@b28-ol-0-0-10024]), the reports are diffuse and contradictory. For example, miRNA-122 acted as a cancer suppressor gene and was downregulated in HCC tissues and cells compared with the adjacent normal tissues and normal cell lines ([@b15-ol-0-0-10024],[@b29-ol-0-0-10024]), which was in line with the results of TCGA analysis. Conversely, the serum expression levels of miRNA-122 increased significantly in HCC patients, hepatitis C patients and other liver injury diseases compared with the healthy controls ([@b30-ol-0-0-10024],[@b31-ol-0-0-10024]). From this perspective, miRNA-122 may be considered an onco-miRNA. In addition, the expression and function of miRNA-122 in other tumors have also been widely reported, including glioma ([@b32-ol-0-0-10024]), renal cell carcinoma ([@b33-ol-0-0-10024]), gastric ([@b34-ol-0-0-10024]) and pancreatic cancer ([@b35-ol-0-0-10024]) and others. In addition to cancer and liver injury diseases, miRNA-122 also served important roles in cardiovascular diseases ([@b36-ol-0-0-10024]--[@b38-ol-0-0-10024]), obesity ([@b39-ol-0-0-10024]--[@b41-ol-0-0-10024]), diabetes ([@b42-ol-0-0-10024]), immunological diseases ([@b43-ol-0-0-10024]--[@b45-ol-0-0-10024]) and other non-cancer diseases ([@b46-ol-0-0-10024]).

The present study analyzed the expression levels of miRNA-122 in tissues and serum samples of various types of cancer systematically by RT-qPCR analysis, TCGA and literature data. The lower expression levels of miRNA-122 in HCC tissues, compared with the adjacent normal tissues, had been validated by a number of researchers over the years ([@b47-ol-0-0-10024],[@b48-ol-0-0-10024]); however, one study has reported conflicting conclusions ([@b49-ol-0-0-10024]). The expression of miRNA-122 was multifarious in different types and degrees of liver cancer and liver injury diseases. From a large classification perspective, the expression levels of miRNA-122 were significantly increased in the serum of HCC patients compared with in healthy controls ([@b50-ol-0-0-10024],[@b51-ol-0-0-10024]). The expression levels of miRNA-122 in the serum of HBV-positive patients with HCC were frequently decreased compared with patients with benign liver lesions ([@b27-ol-0-0-10024]), which was consistent with the results of serological analysis in the present study. Meanwhile, miRNA-122 and AFP analyses were combined for diagnosis in the present study, which may have improved the non-invasive diagnostic accuracy of HCC.

TCGA database is one of the most widely used public data platforms for a variety of types of cancer. Following screening, 17 common cancer types were included in the differential expression analysis of miRNA-122. Finally, it was demonstrated that miRNA-122 was differentially expressed in 10 types of tumor from TCGA. However, by summarizing the reported literature, differential expression of miRNA-122 in a number of types of cancer was also demonstrated. Additionally, there are several consistent types of cancer between the two summary methods, including HCC ([@b52-ol-0-0-10024]), renal carcinoma ([@b33-ol-0-0-10024]) and colorectal cancer ([@b53-ol-0-0-10024]); however, certain results were inconsistent. The number of samples, fixed tumor type in TCGA, the difference in detection methods and platforms, etiology or pathological classification, and clinical features, may lead to inconsistent results. In future studies, an in-depth exploration of inconsistencies can also be conducted. In addition, the prognostic value of miRNA-122 in a variety of cancer was also analyzed and summarized. Through the analysis of TCGA data, it was demonstrated that the expression levels of miRNA-122 could affect the overall survival rate of HCC and renal carcinoma. In addition to the association between miRNA-122 and the prognosis of HCC, it was also demonstrated that the low expression levels of miRNA-122 predicted the poor prognosis of glioma ([@b54-ol-0-0-10024]), gastric cancer ([@b55-ol-0-0-10024]) and leukemia ([@b56-ol-0-0-10024]) by literature retrieval. However, there were disagreements regarding the association between the expression levels of miRNA-122 and the prognosis of HCC in the serum or plasma. Specific studies revealed that high expression of miRNA-122 indicated poor prognosis ([@b57-ol-0-0-10024],[@b58-ol-0-0-10024]), but certain findings suggested that the high expression of miRNA-122 predicted improved prognosis ([@b59-ol-0-0-10024],[@b60-ol-0-0-10024]); however, further investigation is required. Although there are a number of reports on miRNA-122, most of them are limited to a certain cancer, especially liver cancer. In the present study, a more comprehensive pan-cancer analysis of miRNA-122 was performed in combination with the current popular TCGA high-throughput sequencing database and associated literature. The present study is more general, gives a summary and can provide a macro guidance for the diagnosis, prognosis and treatment of multiple cancers in clinical practice.

In this study, the target genes of miRNA-122 were predicted using numerous platforms and the GO and KEGG enrichment analyses were performed on the reported target genes. The results of GO enrichment analysis demonstrated that the target genes of miRNA-122 may contribute to the composition of the nucleus and cytoplasm, and regulate cardiac muscle cell differentiation in a variety of biological processes, including cardiac muscle cell differentiation and glucose metabolic processes through protein binding. So far, numerous articles have reported that miRNA-122 was closely associated with heart-related diseases, obesity and diabetes ([@b37-ol-0-0-10024],[@b61-ol-0-0-10024],[@b62-ol-0-0-10024],[@b64-ol-0-0-10024]). For example, the expression of miR-122 was involved in hypoxia-induced cardiomyocyte injury ([@b37-ol-0-0-10024]). In experiments with miniature pigs, researchers demonstrated that increases in weight and cholesterol levels could lead to a decline in the expression levels of miRNA-122, which supported the association of miRNA122 in obesity ([@b61-ol-0-0-10024]). KEGG pathway analysis revealed that the target genes were mainly enriched in protein biosynthesis, estrogen and glucagon associated signaling pathways. Munagala *et al* ([@b62-ol-0-0-10024]) reported that miRNA-122 was one of the significantly modulated miRNAs in the process of estrogen-mediated mammary carcinogenesis. miRNA-122 participated in the regulation of insulin resistance, diabetes and metabolic syndrome, which were all likely to be associated with glucagon related signaling pathways ([@b42-ol-0-0-10024]).

In conclusion, the clinical significance of miRNA-122 was systematically analyzed from multiple perspectives in this study. The diagnostic value of miRNA-122 between the HCC and healthy control via serology was further demonstrated, and the differential diagnostic value in patients with HCC compared with in benign lesions was also analyzed. In addition, it was demonstrated that miRNA-122 exhibited significant differential expression and prognostic ability in various types of cancer via TCGA database and literature review. Finally, a number of important biological functions and regulatory mechanisms have been reported through the enrichment analysis of the miRNA-122 target genes. These analyses demonstrated that miRNA-122 may be an indispensable biomarker for the diagnosis, prognostic evaluation and targeted therapy in a variety of cancer types.
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###### 

Clinical characteristics of the included individuals.

  Characteristics        HCC                 Hepatitis B   Cirrhosis   Healthy     P-value
  ---------------------- ------------------- ------------- ----------- ----------- ---------
  Mean age ± SD, years   48.6±11.9           42.9±14.4     48.0±11.0   47.2±11.7   \>0.05
  Sex                                                                              
    Male, n (%)          35 (70)             17 (68)       18 (72)     35 (70)     \>0.05
    Female, n (%)        15 (30)             8 (32)        7 (28)      15 (30)     
  AFP, ng/ml             10,676.3±20,568.7   32.4±74.3     20.5±47.5   2.7±1.6     \<0.001
  Cirrhosis                                                                        
    Yes, n (%)           38 (76)             0 (0)         25 (100)    0 (0)       
    No, n (%)            12 (24)             25 (100)      0 (0)       50 (100)    
  Hepatitis B                                                                      
    Yes, n (%)           42 (84)             25 (100)      7 (28)      0 (0)       
    No, n (%)            8 (16)              0 (0)         18 (72)     50 (100)    

Sample sizes in different groups: HCC, n=50; hepatitis B, n=25; cirrhosis, n=25; healthy, n=50. The P-value comparing the difference between the sexes was calculated using χ^2^ test; the P-value comparing the differences between ages and AFP was calculated using a one-way analysis of variance statistical method depending on data normality. HCC, hepatocellular carcinoma; AFP, α-fetoprotein.

###### 

Subgroup analysis of miRNA-122 in HBV-associated individuals.

                         HCC                 Benign          HCC + benign                                                                  
  ---------------------- ------------------- --------------- -------------- ----------- ----------- ------- ---------------- ------------- -------
  miRNA-122, mean ± SD   23.5±29.6           9.5±8.3         0.199          64.3±93.7   35.2±29.5   0.215   28.1±68.6        27.3±27.7     0.324
  AFP, ng/ml             12,588.2±21,920.6   639.1±1,254.2   0.030          33.0±75.0   14.7±26.4   0.634   139.5±17,646.9   206.8±753.3   0.003

Sample sizes: HCC, n=50; benign, n=50. P-value was calculated using Student\'s t-test following normalization (log2 conversion). HCC, hepatocellular carcinoma; AFP, α-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; miRNA, microRNA.

###### 

Diagnostic value of miRNA-122, AFP and miRNA-122 + AFP.

                   HCC vs. Healthy   HCC vs. Benign                                                      
  ---------------- ----------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Sensitivity, %   90.0              86.0             90.0             64.0             86.0             86.0
  Specificity, %   94.0              100.0            100.0            62.0             80.0             80.0
  AUC (95% CI)     0.954             0.961            0.980            0.667            0.878            0.876
                   (0.907--1.000)    (0.927--0.996)   (0.958--1.000)   (0.562--0.772)   (0.811--0.944)   (0.808--0.944)
  PPV, %           94.0              1.0              1.0              63.0             81.0             81.0
  NPV, %           90.0              88.0             91.0             63.0             85.0             85.0
  Cutoff           2.80              8.78                              14.29            8.59             

HCC, hepatocellular carcinoma; AFP, α-fetoprotein; miR, microRNA; AUC, area under curve; PPV, positive predictive value; NPV, negative predictive value.

###### 

Differential expression analysis of microRNA-122 in 17 types of cancer from The Cancer Genome Atlas database.

  Cancer type                             Abbreviation   Cancer/normal, n   False discovery rate                                         LogFC
  --------------------------------------- -------------- ------------------ ------------------------------------------------------------ -------
  Colorectal carcinoma                    CRC            619/11             4.62×10^−2[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^      8.18
  Adrenal gland carcinoma                 AGC            264/3              1.00                                                         7.02
  Cholangiocarcinoma                      CHOL           36/9                 5.01×10^−8[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^    −4.16
  Bladder urothelial carcinoma            BLCA           418/19             3.59×10^−1^                                                  2.04
  Brain glioma                            BG             530/5              1.00                                                         0.45
  Breast cancer                           BC             1,103/104          1.80×10^−13[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^     7.34
  Cervical cancer                         CC             309/3              1.00                                                         6.52
  Esophageal carcinoma                    ESCA           187/13             2.53×10^−1^                                                  3.00
  Head and neck squamous cell carcinoma   HNSC           525/44             7.73×10^−2^                                                  −0.81
  Kidney cancer                           KC             1,074/147            9.40×10^−36[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^   5.43
  Hepatocellular carcinoma                HCC            375/50               1.14×10^−3[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^    −0.61
  Lung cancer                             LC             999/91               9.40×10^−11[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^   5.75
  Pancreatic adenocarcinoma               PAAD           179/4              1.00                                                         0.35
  Prostate adenocarcinoma                 PRAD           499/52             1.19×10^−6[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^      3.84
  Stomach adenocarcinoma                  STAD           446/45             9.86×10^−4[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^      3.44
  Thyroid carcinoma                       THCA           514/59             7.77×10^−3[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^      1.64
  Uterine cancer                          UC             603/33             3.28×10^−5[a](#tfn4-ol-0-0-10024){ref-type="table-fn"}^      6.90

P\<0.05. LogFC, log~2~ (fold-change).

###### 

Differential expression and prognosis evaluation of miRNA-122 in various types of cancer from the reported literature.

  Tumor type                    Sample type    Differential expression (cancer vs. normal)   Overall survival   (Refs.)
  ----------------------------- -------------- --------------------------------------------- ------------------ ----------------------------------------------------------------
  Hepatocellular carcinoma      Tissue         Downregulated                                 Poor               ([@b52-ol-0-0-10024])
  Hepatocellular carcinoma      Plasma/serum   Upregulated                                   Poor               ([@b57-ol-0-0-10024],[@b58-ol-0-0-10024])
  Hepatocellular carcinoma      Plasma/serum                                                 Better             ([@b59-ol-0-0-10024],[@b60-ol-0-0-10024])
  Hepatocellular carcinoma      Plasma/serum   Downregulated                                                    ([@b27-ol-0-0-10024])
  Hepatocellular carcinoma      Plasma/serum   No significance                                                  ([@b49-ol-0-0-10024],[@b63-ol-0-0-10024])
  Glioma                        Tissue         Downregulated                                                    ([@b32-ol-0-0-10024],[@b64-ol-0-0-10024])
  Glioma                        Plasma         Downregulated                                 Poor               ([@b54-ol-0-0-10024])
  Lymphoma                      Plasma         Downregulated                                                    ([@b65-ol-0-0-10024])
  Renal cell carcinoma          tissue         Upregulated                                                      ([@b33-ol-0-0-10024],[@b66-ol-0-0-10024]--[@b71-ol-0-0-10024])
  Gastric cancer                Tissue         Downregulated                                                    
  Gastric cancer                Plasma         Downregulated                                 Poor               ([@b55-ol-0-0-10024])
  Pancreatic cancer             Tissue         Downregulated                                                    ([@b35-ol-0-0-10024],[@b72-ol-0-0-10024])
  Pancreatic cancer             Whole blood    Upregulated                                                      ([@b73-ol-0-0-10024])
  Colorectal carcinoma          Tissue         Upregulated                                                      ([@b53-ol-0-0-10024])
  Colorectal carcinoma          Plasma         Upregulated                                                      ([@b74-ol-0-0-10024])
  Cholangiocarcinoma            Tissue         Downregulated                                                    ([@b75-ol-0-0-10024])
  Gallbladder cancer            Tissue         Downregulated                                                    ([@b76-ol-0-0-10024])
  Prostate cancer               Tissue         Upregulated                                                      ([@b77-ol-0-0-10024])
  Retinoblastoma                Tissue         Downregulated                                                    ([@b78-ol-0-0-10024])
  Osteosarcoma                  Tissue         Downregulated                                                    ([@b79-ol-0-0-10024])
  Breast cancer                 Tissue         Downregulated                                                    ([@b80-ol-0-0-10024]--[@b82-ol-0-0-10024])
  Papillary thyroid carcinoma   Tissue         Upregulated                                                      ([@b83-ol-0-0-10024])
  Pituitary carcinomas          Tissue         Upregulated                                                      ([@b84-ol-0-0-10024])
  Acute myeloid leukemia        Tissue         Downregulated                                 Poor               ([@b56-ol-0-0-10024])
  Bladder cancer                Tissue         Downregulated                                                    ([@b85-ol-0-0-10024])
